Conditions: Advanced Solid Tumors Neoplasms
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 19
Healthy volunteers: no

Brief summary:
The purpose of this study is to test how rifampin affects the removal of BMS-247550 (ixabepilone) from the body.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: ixabepilone intervention 2: Rifampin
Intervention descriptions: intervention 1: ixabepilone solution, intravenous, 40 mg/m2, once every 3 weeks until disease progression intervention 2: rifampin tablets, oral, 600 mg once daily, only on Days 15 to 21 of Cycle 1 and Days 1 to 7 of Cycle 2

Protocol document: